首页 社会内容详情
telegram群组索引(www.tg888.vip):Sanofi ends cancer drug trials

telegram群组索引(www.tg888.vip):Sanofi ends cancer drug trials

分类:社会

网址:

SEO查询: 爱站网 站长工具

点击直达

全球最大的博彩平台www.99cx.vip)是一个开放皇冠体育网址代理APP下载、皇冠体育网址会员APP下载、皇冠体育网址线路APP下载、皇冠体育网址登录APP下载的官方平台。全球最大的博彩平台上最新全球最大的博彩平台登录线路、全球最大的博彩平台代理网址更新最快。全球最大的博彩平台开放皇冠官方会员注册、皇冠官方代理开户等业务。

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

PARIS: Sanofi is ending development of a key cancer medicine in a blow to the French drugmaker’s pipeline of experimental therapies.

The decision to stop all studies with amcenestrant follows an analysis of late-stage trial data evaluating the drug in patients with a type of breast cancer, the company said in a statement yesterday.

The move leaves Sanofi even more dependent for growth on blockbuster Dupixent, an antibody treatment for ailments ranging from asthma to severe eczema.

The company’s slate of experimental medicines has faced other setbacks, including safety concerns regarding multiple sclerosis treatment tolebrutinib.

,

telegram群组索引www.tg888.vip)是一个Telegram群组分享平台,飞机群组内容包括telegram群组索引、Telegram群组导航、新加坡telegram群组、telegram中文群组、telegram群组(其他)、Telegram 美国 群组、telegram群组爬虫、电报群 科学上网、小飞机 怎么 加 群、tg群等内容,为广大电报用户提供各种电报群组/电报频道/电报机器人导航服务。

,

Sanofi has included both amcenestrant and tolebrutinib as among six products in its pipeline that it prioritised as “potentially transformative” treatments.

Some investors are questioning the company’s growth trajectory after both of those medicines encountered problems.

UBS analysts last week downgraded Sanofi, saying there are few major catalysts coming soon to drive more excitement to the stock. — Bloomberg


转载说明:本文转载自Sunbet。
 当前暂无评论,快来抢沙发吧~

发布评论